Gilead Sciences, Inc.

GILD
GILD logo

Statistics

gray dotBusiness Model Rating
$75.88Share Price
$100.1 BMarket Cap
21.4%EBIT / EV
18.5%FCF / EV
738.4%ROIC
637.7%Cash ROIC
48.4%3yr Avg Revenue Growth
4.86Current Ratio
star logo

Business Model Diligence

We have a Business Model Diligence rating and review for this stock, but you must have a MagicDiligence Membership to view it. If you are already a member, you need to log in first.

Statistical Diligence

gray wandCurrent member of one or more spells! Log in to see which ones.
check mark The EBIT / Enterprise Value of 21.4% ranks as Very High.
check mark The Free Cash Flow / Enterprise Value of 18.5% ranks as Very High.
check mark The Return on Invested Capital Value of 738.4% ranks as Suspicious.
check mark The Cash Return on Capital Value of 637.7% ranks as Suspicious.
check mark The 3 Year Average Revenue Growth Value of 48.4% ranks as Very High.
check mark Near-term Financial Health appears to be Very Good. The Current Ratio is 4.86.

Company Description

Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Calculations

You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.